Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Zymergen Inc. Shareholders

Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Zymergen Inc. (“Zymergen”) (NASDAQ: ZY) securities pursuant to its initial public offering on or around April 21, 2021.

Zymergen investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.

On August 3, 2021, Zymergen shocked the market when it gave a “business update” and announced that several of its key target customers faced “technical issues” in implementing Hyaline – its first product – into their manufacturing processes.  Zymergen also announced that, as a result, it will delay its ramp-up, doesn’t expect to generate any product revenue in 2021 and expects product revenue to be “immaterial” in 2022.  The company also revealed that its Chief Executive Officer, Josh Hoffman, had stepped down effective immediately. 

In response to this news, Zymergen’s stock price has fallen by more than 77%.  

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  James Maro, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected].